Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours.
The response to a single course of carboplatin has been investigated in 12 patients with previously untreated non-seminomatous testicular germ cell tumours. Patients received one course of carboplatin at a dose calculated to achieve a target area under the free carboplatin plasma concentration versus time curve (AUC) of 7 mg/ml x mins using the formula: dose (mgs) = target AUC x (GFR + 25). Response to carboplatin was assessed after a single course and treatment was then continued on the POMB/ACE schedule. Ten of 12 patients had either a greater than 50% decrease in serum HCG and/or AFP levels or a greater than 50% decrease in tumour volume after a single course of carboplatin. No patient had evidence of disease progression after carboplatin. This study demonstrates that single agent carboplatin is highly active in patients with non-seminomatous testicular germ cell tumours and thus provides evidence to justify its inclusion in chemotherapy combinations.
O'Reilly
S M
SM
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom.
Rustin
G J
GJ
Smith
D B
DB
Newlands
E S
ES
D016190:Carboplatin / Q000627:therapeutic use*; D006063:Chorionic Gonadotropin / Q000097:blood; D004407:Dysgerminoma / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D011446:Prospective Studies; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D000509:alpha-Fetoproteins / Q000032:analysis
D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D016190:Carboplatin